Black Americans with chronic kidney disease (CKD) have high rates of uncontrolled hypertension. 1 Uncontrolled hypertension is a major risk factor for the development of CKD, progression to kidney failure, and death from cardiovascular disease (CVD). 2, 3 CVD is the leading cause of death among blacks with CKD and CVD mortality rates are twice as high in blacks with CKD compared to blacks with normal kidney function. 4 Diet is a major disease modifier of both hypertension and CVD. Therefore, identifying dietary patterns that improve hypertension control rates among blacks with CKD could positively impact kidney and CVD outcomes for this patient population.
DASH diet improved BP in 7 out of 10 hypertensive black adults with moderate CKD. 22 It is not clear whether DASH lowers BP in blacks with CKD without concomitant sodium reduction. In this study, we evaluated the association of DASH accordance (without explicit sodium reduction) with BP and prevalent hypertension among a population-based cohort of black Americans with and without CKD enrolled in the Jackson Heart Study (JHS). 23 
METHODS

Study population
The JHS is the largest longitudinal, population-based study designed to investigate causes of CVD among black Americans. 23, 24 From 2000 to 2004 (Exam 1), the JHS enrolled 5,306 adults residing in metropolitan Jackson, MS between 21 and 95 years old. After obtaining written informed consent, trained staff performed baseline assessments to ascertain data on sociodemographic, behavioral, and biological risk factors for CVD. Our study involves JHS participants who completed baseline food frequency questionnaires (FFQ) and measurements of office BP, serum creatinine concentration, and urine creatinine and albumin concentrations. We excluded participants with indeterminant CKD status, invalid FFQ data (defined as daily energy intake ≤600 kcal or ≥4,800 kcal or suspicion of inaccurate reporting), or missing covariate data for education, alcohol intake, smoking status, and body mass index. The protocol was approved by institutional review boards at each participating site and this study was approved by the Duke Health Institutional Review Board.
Assessments
DASH scores. Participants' usual dietary patterns were assessed using the Delta Nutrition Intervention Research Initiative FFQ, a validated 158-item region-specific diet assessment tool. 25 Participants' diet was assessed using the nutrient-based DASH accordance score derived by Mellen et al. 26 To determine the DASH score, 26 participants were assigned an intermediate point or full point (0.5 or 1 point, respectively) for achieving daily nutrient targets for total fat, saturated fat, protein, cholesterol, fiber, magnesium, calcium, potassium, and sodium (Table 1) . In order to evaluate the relationship between DASH accordance and outcomes, independent of dietary sodium intake, we excluded sodium from our composite score and report results based on a oneunit change (i.e., 1 point) in the 8-variable DASH score unless stated otherwise.
Blood pressure. BP was obtained after participants rested quietly for 5 minutes in a seated position with their back and arm supported, legs uncrossed, and feet flat on the floor. Two BP measurements were obtained 1 minute apart and averaged. BP was measured using a random-zero sphygmomanometer (Hawksley and Sons, Lancing, United Kingdom) 27 at Exam 1 (2000) (2001) (2002) (2003) (2004) and a semiautomated oscillometric device (Omron HEM-907XL) at follow-up visits. To improve the generalizability of statistical inferences of longitudinal data, a BP-comparability substudy was performed in 2,115 participants whose BP was measured simultaneously with a random-zero sphygmomanometer and the oscillometric device using a Y-connector at Exam 2 (2005 Exam 2 ( -2008 , permitting calibration of random-zero BP measurements to semiautomated measurements using robust regression. 28 We used calibrated BP values for the current analyses. Hypertension was defined as mean systolic BP (SBP) ≥140 mm Hg, or mean diastolic BP (DBP) ≥90 mm Hg, or use of antihypertensive medications.
Kidney function. Serum creatinine, urine albumin, and urine creatinine concentrations were measured at baseline. We used the creatinine-based CKD-EPI equation to determine estimated glomerular filtration rate (eGFR). 29 We used spot urine samples, or 24-hour urine samples when spot samples were unavailable, to determine urine albumin-tocreatinine ratio (ACR). We defined CKD as eGFR <60 ml/ min/1.73 m2 and/or presence of albuminuria. Albuminuria was defined as ACR ≥30 mg/g. CKD status was indeterminant for participants with an eGFR ≥60 ml/min/1.73 m2 and missing ACR, or missing eGFR and ACR <30 mg/g. We classified CKD as stage 1 for eGFR ≥90 ml/min/1.73 m2 and ACR ≥30 mg/g, stage 2 for eGFR 60-89 ml/min/1.73 m2 and ACR ≥30 mg/g, stage 3 for eGFR 30-59 ml/min/1.73 m 2 , stage 4 for eGFR 15-29 ml/min/1.73 m 2 , stage 5 for eGFR <15 ml/min/1.73 m 2 , and unstageable for ACR ≥30 mg/g and missing eGFR.
Covariates. Surveys were administered to collect data on participants' medical histories, medication use, household income, smoking status, education, alcohol use, and physical activity level. A description of data collection methods for each covariates and definitions for diabetes, body mass 
Statistical analysis
We performed descriptive statistics to assess participant characteristics overall and by CKD status. We used linear regression models for continuous BP outcomes (i.e., SBP and DBP) and a modified Poisson regression model with robust standard errors for hypertension in order to estimate the prevalence ratio (PR). Models were adjusted for participants' age, sex, income, education, smoking status, alcohol use, physical activity, and body mass index. Models estimating the associations between the DASH score and SBP or DBP were also adjusted for participants' use of antihypertensive medications. We performed tests for interaction between CKD and the DASH score to determine the effect modification of CKD on primary associations. We also examined correlations between the DASH score and daily sodium intake. To determine if our inference was sensitive to dietary sodium, we adjusted our BP models for absolute daily sodium intake and also performed separate analyses using a 9-variable DASH score 26 that included a score for dietary sodium. We also conducted separate sensitivity analyses to test for an interaction effect of albuminuria (defined as ACR ≥30 mg/g-an independent marker of kidney dysfunction) within multivariable models quantifying the association between the DASH score and SBP or DBP while adjusting for age, sex, income, education, smoking status, alcohol use, physical activity, body mass index, and eGFR, including a DASH score × albuminuria interaction term. To determine if our inference was sensitive to the moderate amount of missing data related to indeterminant CKD status, we conducted two extreme-case analyses in which we assumed all missing CKD data were not CKD, or alternatively, that all were prevalent CKD. In a post hoc analysis, we evaluated the effect modification of continuous eGFR, instead of CKD, on diet and prevalent hypertension. All hypotheses tests were two sided at the 0.05 level for main effects and 0.10 level for interaction effects. Statistical analyses were performed using R version 3.4.4 (Vienna, Austria) and SAS 9.4 (SAS institute, Cary, NC).
RESULTS
Study population
Of 5,306 total JHS participants, 2,171 (41%) were excluded ( Figure 1 ) and their baseline characteristics were similar to participants remaining in our final analytic sample (Supplementary Table 1 ). Among the 3,135 participants included, mean age was 55 years, mean eGFR was 93 ml/min/1.73 m2, and 60% had hypertension. Compared to participants without CKD, participants with CKD were older, had less education, had lower household income, were less physically active, had higher prevalence of hypertension and diabetes, and had higher mean SBP ( Table 2 ). The prevalence of CKD stage 1 was 32%, stage 2 was 19%, stage 3 was 41%, stage 4 was 4%, stage 5 was 3%, and CKD stage could not be determined for the 1% with known ACR but unknown creatine values. Table 2 ).
Relation between DASH accordance and BP
CKD status modified the relation of the DASH score to both SBP and DBP (P interactions = 0.06 and 0.01, respectively; Figure 3 ). Among participants without CKD, the DASH score was not associated with SBP or DBP (−0.4 [−1.0, 0.1] mm Hg and −0.1 [−0.4, 0.2] mm Hg per one unit higher DASH score, respectively). However, among participants with CKD, there was a statistically significant inverse association between the DASH score and BP; one unit higher DASH score was associated with lower SBP by 1.6 (0.5, 2.6) mm Hg and lower DBP by 0.9 (0.3, 1.5) mm Hg (Figure 3 ) on average.
Relation between DASH accordance and prevalent hypertension
In cross-sectional analyses, CKD modified the association between the DASH score and prevalent hypertension (P interaction = 0.01). Among those without CKD, one unit higher DASH score was associated with higher prevalence of hypertension by 4% (PR: 1.04 [1.01, 1.07]). However, among those with CKD, this association was not present (PR: 0.99 [0.96, 1.02] per one unit higher DASH score).
Sensitivity analyses
Controlling for dietary sodium intake. Consistent with our main findings, when a variable for dietary sodium was included Effect modification of albuminuria on diet and BP. In multivariable models adjusted for our prespecified covariates and eGFR, albuminuria modified the relation of the DASH score to both SBP and DBP (P interactions were <0.01 and 
Extreme cases analyses of missing CKD data.
When the BP main analyses were repeated under the two extreme assumptions, the interaction effects were strengthened when all missing data were assumed as non-CKD, and attenuated when all missing data were assumed to be CKD. In the latter case, though no longer statistically significant, the direction of the effects did not change. The statistical inference for prevalent hypertension was not sensitive to either extreme assumption.
Post hoc analysis. When we substituted CKD status with eGFR in our multivariable models for prevalent hypertension adjusting for participants' age, sex, income, education, smoking status, alcohol use, physical activity, body mass index, and continuous eGFR, the association between DASH score and prevalent hypertension was statistically significant (PR: 1.02 [1.00, 1.04] per one unit higher DASH score).
DISCUSSION
Among 3,135 participants enrolled in the JHS, greater accordance to DASH was associated with lower SBP and DBP levels. Despite DASH scores being low overall, the association between DASH accordance and BP was more favorable among participants with CKD compared to those without CKD. Results from our pilot feeding study previously demonstrated that DASH improves BP among black adults (N = 10) with CKD. 30 Our current study expands those findings to a larger sample of black Americans and provides additional evidence that the relationship between DASH accordance and BP is modified by markers of kidney function. 31 The degree to which JHS participants adhered to DASH is consistent with dietary patterns in other US-based populations. For example, using a 9-point scale, median DASH scores were 1.5 among an urban population-based cohort of 1,534 middle-aged black and white adults 32 and 2.9 among a random population sample of 2007-2012 National Health and Nutrition Examination Survey participants (N = 5,848), 33 compared to a median of 1 on an 8-point scale in our final analytic sample. In both studies, no participants met full DASH accordance and black race was associated with lower DASH scores. 32, 33 Our data in an exclusively black sample suggest that black adults with CKD may benefit from DASH even when accordance is suboptimal. If confirmed, it is important to note that sodium reduction is the only diet modification that is currently endorsed by national and international kidney disease guidelines to lower BP in adults with CKD. 20, 21 Our study provides important evidence that non-sodium-based diet modifications may also lower BP in blacks with CKD.
Although randomized controlled trials have consistently demonstrated that DASH lowers BP in adults with normal kidney function, [5] [6] [7] 18, 34, 35 we only observed a statistically significant inverse association between DASH accordance and BP among JHS participants with CKD. It is possible that the degree of DASH accordance among our sample was not high enough for us to observe an association between DASH score and BP overall. However, our findings are important because they raise the possibility that DASH may benefit BP in adults with CKD at lower degrees of accordance than what is needed to benefit adults with normal kidney function.
Increased effectiveness of DASH in CKD, compared to non-CKD, is plausible because several pathologic mechanisms that contribute to hypertension in CKD, such as reduced natriuresis, upregulated renin-angiotensin-aldosterone system activity, 16 increased sympathetic nervous system activity, 36 and impaired nitric-oxide-induced endothelium-mediated vasodilatation, 37 are all potential mechanisms proposed to be mitigated by DASH. 17, 18 We previously reported evidence that kidney function markers modulate the relationship between BP and diet in a post hoc analysis of the DASH trial. 31 Our results demonstrated that subclinical kidney dysfunction (defined as daily urine albumin excretion ≥7 mg/day) was associated with enhanced BP response to DASH. Our current study expands those findings by showing that urine albumin excretion at concentrations of 30 mg/g or more modifies the association between DASH accordance and BP in a larger cohort. The safety of DASH must be established in CKD considering DASH is higher in potassium, phosphorus, and protein than what is currently recommended by National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines for adults with CKD stages 3 or higher. 21 Our pilot feeding study demonstrated that adults with moderate CKD can consume DASH for a short term without developing incident hyperkalemia, hyperphosphatemia, or metabolic acidosis. 22 However, longer term, randomized controlled studies are needed to confirm those findings. Evidence from other studies also suggests a DASH dietary pattern may be safe in CKD. For example, serum potassium concentrations did not increase in adults with hypertensive CKD stage 4 who consumed a high fruit and vegetable diet for 1 year. 38 The absence of hyperkalemia and observation of improved metabolic acidosis, markers of kidney injury, and BP among participants in that study 38 suggest that DASH may be safe and provide additional health benefits in CKD. Furthermore, greater accordance to DASH has been associated with lower risk for incident CKD 39 and kidney function decline 40 in US population-based studies. Our observation that there was a strong association between diet and BP among participants with CKD despite participants having an overall low accordance rate to daily targets for potassium, calcium, magnesium, and protein consumption raises the potential for a DASH-style dietary pattern to be beneficial even if the content of these nutrients was reduced to meet kidney-related diet safety concerns.
The cross-sectional association between greater DASH accordance with higher prevalence of hypertension among JHS participants without CKD was unexpected. This finding may reflect participants with hypertension having a greater likelihood of being advised to follow healthful diets like DASH. As observations were cross-sectional, we cannot draw inferences regarding any causal associations.
Strengths of our study include its large sample size of black Americans, prevalent CKD, and assessment of diet using a regionally validated FFQ. Limitations of our study include its cross-sectional design that precludes determination of causal relationships; single timepoint measurements of serum creatinine and urine albumin, which may result in misclassification of CKD; intrinsic limitations of FFQ data involving recall bias and reporting error; potential selection bias with exclusion of 41% of the JHS participants; and defining hypertension by participant self-report, mean BP values obtained at single clinic visits, and use of antihypertensive agents, which may result in misclassification of hypertension. Although we adjusted for several demographic and health behaviors that influence diet and BP, our results could have also been impacted by unmeasured confounders. The generalizability of our results to non-black racial groups and individuals with CKD stages 4 and 5 (which only comprised 7% of our CKD population) is also limited. In conclusion, our findings suggest that CKD may be a compelling indication to recommend DASH to black patients due to its favorable association with BP, even at low levels of DASH accordance. Randomized controlled studies are needed to confirm the efficacy and test the safety of DASH on BP in black adults with moderate and severe CKD.
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